Lunch with LifeSci: Featuring Eledon Pharmaceuticals
About The Event
Please join us on July 26th at 12:00 pm ET for LifeSci’s virtual webinar series “Lunch with LifeSci” featuring David-Alexandre (DA) C. Gros, M.D., CEO of Eledon Pharmaceuticals, a clinical stage biotech using its immunology expertise to develop therapies to better protect and extended the functional life of transplanted organs.
Our “Lunch with LifeSci” series highlights promising healthcare investment opportunities by simplifying the complex for the generalist investor who is seeking outperformance in their investment portfolio.
Eledon Pharma is currently initiating BESTOW, a Phase 2, 120 patient, superiority trial assessing tegoprubart vs. standard of care (tacrolimus) in the protection of kidneys and preservation of graft function after kidney transplantation. The company is also conducting a Phase 1b, 12 patient, open label trial evaluating the safety and efficacy of tegoprubart in kidney transplantation. The company reported interim data from the Phase 1b trial in April 2023 with the next readout expected later in the year.
Tegoprubart is a novel monoclonal antibody that exhibits a broad anti-inflammatory capability by inhibiting CD40/CD40L binding, a key component in both adaptive (i.e., T and B cell) and innate (e.g., macrophage and dendritic cell) immune system cell activation and function.
With 25,000 yearly kidney transplants in the United States and over 240,000 Americans living with a kidney graft, the market potential for tegoprubart is tremendous. Tacrolimus, the current first line anti-rejection therapeutic for kidney transplantation was approved by the FDA in 1994 and has significant toxicities, making the market ripe for improvement.
On May 1, 2023, Eledon Pharma completed a financing of up to $185 million, led by existing shareholder BVF Partners, alongside new investors Armistice Capital and Sanofi. The recent financing, subject to achieving future milestones, is expected to be sufficient to fund Eledon Pharma through the completion of both the Phase 1b and Phase 2 BESTOW kidney transplant trials.
Join us as we speak with DA Gros, CEO of Eledon Pharma to learn why tegoprubart has the opportunity to revolutionize post-transplant therapeutics and improve the lives of transplant recipients.